Big Pharma CEOs Rake in Millions in Compensation While Patients Struggle With Sky-High Drug Prices

 

• BioNTech’s Dr. Ugur Sahin topped Fierce Pharma‘s 2024 list with $287 million, while Pfizer’s Albert Bourla ($24.6 million) and Eli Lilly’s David Ricks ($29.2 million) ranked among the highest-paid, reflecting booming drug sales (e.g., weight-loss drugs, COVID-19 vaccines).
• Executives’ multimillion-dollar payouts contrast sharply with soaring prescription costs, eroding public trust as patients struggle to afford medications like insulin.
• Major firms (Merck, Bristol Myers Squibb, AstraZeneca, J&J) are suing to block Medicare price negotiations, while industry lobbying fights to maintain high drug prices despite evidence of greater spending on stock buybacks than R&D.
• Executives at Pfizer, Moderna and J&J cashed out $250 million in stocks post-Operation Warp Speed, while Moderna’s CEO earned $392 million in 2023 despite missing the 2024 list.
• Critics highlight a rigged system where executive bonuses and corporate profits take priority over affordable healthcare, widening the gap between boardroom gains and patient hardships.

(Natural News)—As Big Pharma executives continue to amass staggering fortunes, patients face soaring prescription costs and dwindling trust in an industry that profits from lifesaving medicines.

Fierce Pharma released its Top 10 highest-paid pharmaceutical executives list for 2024 on Monday, June 16. BioNTech’s Dr. Ugur Sahin topped the list at $287 million – nearly 10 times more than his closest competitor. Eli Lilly’s David Ricks, who landed on No. 2, secured $29.2 million amid booming sales of weight-loss drugs Zepbound and Mounjaro.

https://americafirstreport.com/big-pharma-ceos-rake-in-millions-in-compensation-while-patients-struggle-with-sky-high-drug-prices/